The remodelling of the tumour chemokine/receptor landscape and the increased persistence of CD8+ T cells lacking Cbx3/HP1γ allows their optimum invasion into tumours at the cost of CD4+ Tregs. This evidence concerns the gene CBX3 and neoplasm.